Wegner 2004.

Methods	A prospective randomized 3‐arm multi‐centre clinical trial at 6 military hospitals in the USA
Participants	450 participants Inclusion: at least 18 years of age, receiving a stable ART regimen containing ≥ 2 drugs for at least 8 weeks before randomization, able to provide informed consent, willing to attend regular study visits Exclusion: not reported
Interventions	Intervention 1: routine access to phenotype testing (PT) Intervention 2: routine access to genotype testing (GT) Control: no access to resistance testing (VB)
Outcomes	Treatment failure, discontinuation
Notes	All participants provided informed consent. Funding: US Army Medical Research and Material Command and the Henry M. Jackson Foundation for the Advancement of Military Medicine
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of randomization was not reported.
Allocation concealment (selection bias)	Low risk	The randomization procedure was centrally located.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	This was an open‐label study (knowledge of allocation is unlikely to introduce bias).
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Trial authors did not report this information (knowledge of allocation is unlikely to introduce bias).
Incomplete outcome data (attrition bias) All outcomes	High risk	Losses to follow‐up were balanced between groups but were considerable (> 65%).
Selective reporting (reporting bias)	High risk	Only treatment failure and discontinuation were reported.
Other bias	Low risk	We found no other sources of bias.
Overall risk assessment	High risk	Risk is due to the uncertainties raised above.

Abbreviations: ART: antiretroviral therapy; CG: control group; EA: expert advice; G: genotyping; GART: genotypic antiretroviral resistance testing; GG: genotypic group; GT: genotype testing; ITT: intention‐to‐treat; NNRTI: non‐nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; P: phenotyping; PI: protease inhibitor; PRT: phenotypic resistance testing; PT: phenotype testing; SOC: standard of care; VB: XXX; VL: viral load.